Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Genomics Adds Kinase to Collaboration with Serono

NEW YORK, Nov. 19 (GenomeWeb News) - Cellular Genomics said today it has added an additional drug target to its kinase discovery collaboration with Serono.

 

Under the agreement, Cellular Genomics will use its Analog Sensitive Kinase Allele technology to produce modified kinases for Serono, and will use its P-inhibitor technology to study consequences of kinase inhibition in vivo and to map kinase signaling pathways for Serono.

 

The Brandord, Conn.-based chemical genomics company, first signed the agreement with Serono in October 2002, to apply its chemical genetics technologies to four kinase drug targets that Serono had selected. Cellular Genomics' ASKA   technology consists of   genetically modified kinases that act like normal kinases, but can be selectively and specifically inhibited with a small-molecule inhibitor the company has designed.

 

The parties did not disclose the financial terms of the agreement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.